MX2021001287A - Métodos para tratar trastornos neurodegenerativos. - Google Patents
Métodos para tratar trastornos neurodegenerativos.Info
- Publication number
- MX2021001287A MX2021001287A MX2021001287A MX2021001287A MX2021001287A MX 2021001287 A MX2021001287 A MX 2021001287A MX 2021001287 A MX2021001287 A MX 2021001287A MX 2021001287 A MX2021001287 A MX 2021001287A MX 2021001287 A MX2021001287 A MX 2021001287A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- neurodegenerative disorders
- treating neurodegenerative
- treating
- disorders
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Aminopropanesulfonate Chemical compound NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960003570 tramiprosate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862713061P | 2018-08-01 | 2018-08-01 | |
| PCT/US2019/044023 WO2020028290A1 (en) | 2018-08-01 | 2019-07-30 | Methods for treating neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021001287A true MX2021001287A (es) | 2021-07-15 |
Family
ID=67614642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021001287A MX2021001287A (es) | 2018-08-01 | 2019-07-30 | Métodos para tratar trastornos neurodegenerativos. |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US12083082B2 (https=) |
| EP (1) | EP3829563B1 (https=) |
| JP (1) | JP7573512B2 (https=) |
| KR (1) | KR102716959B1 (https=) |
| CN (1) | CN112867485A (https=) |
| AU (1) | AU2019315853B2 (https=) |
| BR (1) | BR112021001739A2 (https=) |
| CL (1) | CL2021000269A1 (https=) |
| DK (1) | DK3829563T3 (https=) |
| EA (1) | EA202190406A1 (https=) |
| ES (1) | ES3011716T3 (https=) |
| FI (1) | FI3829563T3 (https=) |
| HR (1) | HRP20250206T1 (https=) |
| HU (1) | HUE070101T2 (https=) |
| IL (1) | IL280424B2 (https=) |
| LT (1) | LT3829563T (https=) |
| MX (1) | MX2021001287A (https=) |
| MY (1) | MY206530A (https=) |
| PH (1) | PH12021550213A1 (https=) |
| PL (1) | PL3829563T3 (https=) |
| PT (1) | PT3829563T (https=) |
| RS (1) | RS66516B1 (https=) |
| SG (1) | SG11202100767XA (https=) |
| SI (1) | SI3829563T1 (https=) |
| SM (1) | SMT202500080T1 (https=) |
| UA (1) | UA130011C2 (https=) |
| WO (1) | WO2020028290A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021025504A2 (pt) * | 2019-06-17 | 2022-04-26 | Alzheon Inc | Métodos para tratar distúrbios neurodegenerativos |
| MX2024007070A (es) * | 2021-12-09 | 2024-08-22 | Alzheon Inc | Alz-801 para uso en el tratamiento de la enfermedad de alzheimer. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840294A (en) | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| PT2089417E (pt) | 2006-10-12 | 2015-04-14 | Bhi Ltd Partnership | Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico |
| WO2013177367A2 (en) | 2012-05-23 | 2013-11-28 | The Johns Hopkins University | Compounds and methods of use thereof for treating neurodegenerative disorders |
| WO2014121083A1 (en) | 2013-01-31 | 2014-08-07 | President And Fellows Of Harvard College | Methods of increasing neuronal connectivity and/or treating a neurodegenerative condition |
| CA2941415A1 (en) * | 2014-03-21 | 2015-09-24 | Alzheon, Inc. | Methods for treating neurological disorders |
| FI3347002T3 (fi) | 2015-09-10 | 2023-08-10 | Alzheon Inc | Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa |
-
2019
- 2019-07-30 JP JP2021505721A patent/JP7573512B2/ja active Active
- 2019-07-30 HU HUE19752795A patent/HUE070101T2/hu unknown
- 2019-07-30 SG SG11202100767XA patent/SG11202100767XA/en unknown
- 2019-07-30 FI FIEP19752795.5T patent/FI3829563T3/fi active
- 2019-07-30 CN CN201980064415.6A patent/CN112867485A/zh active Pending
- 2019-07-30 SM SM20250080T patent/SMT202500080T1/it unknown
- 2019-07-30 US US17/264,477 patent/US12083082B2/en active Active
- 2019-07-30 EA EA202190406A patent/EA202190406A1/ru unknown
- 2019-07-30 EP EP19752795.5A patent/EP3829563B1/en active Active
- 2019-07-30 BR BR112021001739-9A patent/BR112021001739A2/pt unknown
- 2019-07-30 RS RS20250164A patent/RS66516B1/sr unknown
- 2019-07-30 PT PT197527955T patent/PT3829563T/pt unknown
- 2019-07-30 AU AU2019315853A patent/AU2019315853B2/en active Active
- 2019-07-30 WO PCT/US2019/044023 patent/WO2020028290A1/en not_active Ceased
- 2019-07-30 IL IL280424A patent/IL280424B2/en unknown
- 2019-07-30 KR KR1020217005803A patent/KR102716959B1/ko active Active
- 2019-07-30 MY MYPI2021000515A patent/MY206530A/en unknown
- 2019-07-30 DK DK19752795.5T patent/DK3829563T3/da active
- 2019-07-30 LT LTEPPCT/US2019/044023T patent/LT3829563T/lt unknown
- 2019-07-30 ES ES19752795T patent/ES3011716T3/es active Active
- 2019-07-30 PL PL19752795.5T patent/PL3829563T3/pl unknown
- 2019-07-30 SI SI201930898T patent/SI3829563T1/sl unknown
- 2019-07-30 HR HRP20250206TT patent/HRP20250206T1/hr unknown
- 2019-07-30 MX MX2021001287A patent/MX2021001287A/es unknown
- 2019-07-30 UA UAA202101015A patent/UA130011C2/uk unknown
-
2021
- 2021-01-28 PH PH12021550213A patent/PH12021550213A1/en unknown
- 2021-02-01 CL CL2021000269A patent/CL2021000269A1/es unknown
-
2024
- 2024-08-02 US US18/793,452 patent/US20250213507A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2018000242A (es) | Moduladores del camino de estrés integrado | |
| MX2023013164A (es) | Agentes radioterapeuticos y de imagenologia que se dirigen a proteina-alfa de activacion fibroblastos (fap-alfa). | |
| CL2019001709A1 (es) | Derivados pirazol como inhibidores de malt1. | |
| NI201900070A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2020002573A1 (es) | Inhibidores atf6 y sus usos. | |
| PT3873604T (pt) | Métodos para tratar a doença de alzheimer com hp-[beta]-ciclodextrina | |
| CL2024002173A1 (es) | Bis-octahidrofenantreno carboxamidas y conjugados de proteínas de las mismas | |
| ECSP20030074A (es) | Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson | |
| MX392026B (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| BR112018010216A2 (pt) | purinonas como inibidores da protease específica da ubiquitina 1 | |
| DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| MX375424B (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl | |
| CR20200214A (es) | ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| EP3487507A4 (en) | VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE | |
| IL286340A (en) | Topical formulations for treatment of peripheral neuropathies | |
| IL263433A (en) | Methods for treating alzheimer's disease | |
| IL280315A (en) | Methods of treatment and prevention of alzheimer's disease | |
| GT201700223A (es) | Imidazopirazinonas como inhibidores de pde 1 | |
| MX2018001592A (es) | Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos. | |
| BR112018003800A2 (pt) | derivados de 1,7-diaril-1,6-heptadieno-3,5-diona, processo para a sua produção e utilização | |
| MX378739B (es) | Compuestos de 2-oxindol. | |
| MX2023012640A (es) | Uso de profarmacos de riluzol para tratar ataxias. | |
| MX377304B (es) | Derivados de piperazina como moduladores de los receptores x del hígado. | |
| MX2016012784A (es) | Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones. |